Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
EUDA Catalyst Timeline
Dated clinical, regulatory and corporate events for EUDA Health Holdings Limited
Past FDA Catalysts and PDUFA Decisions
How EUDA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
EUDA Health Holdings Limited is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every EUDA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tan Meng Dong (James)10% Owner | Other | 2,776,000 2,776,000 held | $0.00 | 11/17/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in EUDA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in EUDA for Q3 2026. | ||||
Ownership Trends
EUDA Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How EUDA ranks across every disease it competes in
EUDA News
EUDA Health Subsidiary Melana International Wins Golden Bull Award 2026 Singapore
EUDA Health Holdings Limited announced that subsidiary Melana International won the Golden Bull Award 2026 in Singapore. The award recognizes small and medium-sized enterprises based on financial performance and business resilience. Melana manages 33 properties across Singapore, including 5,488 residential and commercial units. The company also received five other accolades in 2026 for its property management services.
Read more →EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore
EUDA Health Holdings subsidiary Melana International won the SME100 Awards 2026 in Singapore. The award recognizes Melana's strong revenue growth and business strategy in property management. Melana manages 31 properties across Singapore, including 5,675 residential and commercial units. This win adds to four other accolades the company received in 2026.
Read more →EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market's Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
EUDA Health Holdings Limited has regained compliance with the Nasdaq Capital Market's continued listing requirements after a prior notification regarding a minimum market value deficiency. The company received a notice on April 23, 2026, for failing to meet the minimum market value of $35 million for over 32 consecutive business days. However, a subsequent notice on May 28 confirmed that the company had maintained the required market value for ten consecutive business days, restoring its compliance status.
Read more →EUDA Health Expands Helix Product Line with Launch of Regenix iPSC-Derived Skin Stem Cell Secretome Mask
EUDA Health Holdings Limited announced the expansion of its Helix product line with the launch of the Regenix iPSC-derived Skin Stem Cell Secretome Mask. This face mask utilizes advanced secretome technology aimed at enhancing skin hydration and recovery. With the global face mask market projected to grow significantly, EUDA plans to capitalize on its distribution networks and partnerships to drive sales in Asia-Pacific, particularly focusing on market demand in countries like China and Malaysia.
Read more →EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
EUDA Health Holdings Limited announced that Shenzhen Inno Immune Co., Ltd. has received approval for its TCR-T cell therapy project under the Shenzhen Key Industry R&D Program. This government initiative aims to support technological innovation and industrial development, with funding of approximately US$434,688 expected for the project. The therapeutic focus is on developing TCR-T therapies targeting solid tumors, utilizing cutting-edge AI-driven screening technologies. This collaboration positions EUDA to expand its distribution of advanced treatments and underscores its commitment to innovative healthcare solutions.
Read more →EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities
EUDA Health Holdings Limited has received a notice from Nasdaq indicating its failure to maintain the minimum market value of listed securities at $35 million. The company has a compliance period of 180 days, until October 20, 2026, to meet the required market value for at least ten consecutive business days. Failure to comply could result in delisting, although the company may appeal any delisting determination from Nasdaq. There are no assurances that compliance can be regained during this period.
Read more →EUDA Announces Reverse Stock Split of its Ordinary Shares
EUDA Health Holdings Limited has announced a reverse stock split of its ordinary shares at a 1-for-20 ratio, effective March 23, 2026. This decision, approved by its Board of Directors, aims to consolidate shares and potentially enhance share price perception in the market. Following the split, the outstanding ordinary shares will decrease from approximately 50.3 million to about 2.5 million. EUDA, with its basis in Singapore and focus on non-invasive healthcare, aims to lead the preventive care sector amid shifting demographics in Asia.
Read more →EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant
EUDA Health Holdings Limited has announced the successful repurchase and cancellation of a warrant issued to Streeterville Capital, LLC, eliminating the potential issuance of 2,000,000 ordinary shares. The repurchase was completed for a total of US$125,000 as part of a securities purchase agreement made in November 2025. This strategic action demonstrates EUDA's commitment to maintaining shareholder value while focusing on the growing longevity healthcare market in Asia.
Read more →EUDA Health Announces Second Amendment to Streeterville Warrant Agreement
EUDA Health Holdings Limited has announced a second amendment to its warrant agreement with Streeterville Capital, reducing the exercise price from $4.00 to $2.00 per share. This adjustment also lowers the minimum closing price requirement for forced exercise from $6.00 to $3.00. CEO Alfred Lim stated that this change is aimed at aligning the warrant terms with current market conditions while maintaining focus on the company's long-term strategy. The company continues to prioritize preventive and longevity-focused healthcare solutions in Asia.
Read more →EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
EUDA Health Holdings Limited has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd., marking a strategic expansion of its stem cell therapy platform. The agreement involves an investment of up to RMB 6 million, aimed at enhancing Shenzhen Inno's production and innovation capabilities. This investment will serve as a core hub for EUDA's operations in China and is structured to enable potential equity conversion in the future. With strong institutional backing and a focus on advanced cellular therapeutics, EUDA continues to position itself as a leader in non-invasive healthcare in Asia.
Read more →EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement
EUDA Health Holdings Limited has announced an amendment to its warrant agreement with Streeterville Capital, reducing the exercise price from $6.00 to $4.00 per share. This amendment may stimulate warrant exercises and further involvement in EUDA's growth strategy. The company operates in the non-invasive healthcare sector in Asia, targeting key markets like Singapore, Malaysia, and China, and focuses on addressing the needs of an aging population. EUDA aims to become a leader in longevity-focused healthcare solutions.
Read more →EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital SINGAPORE
EUDA Health Holdings Limited has announced the launch of a nationwide stem cell extraction, cryostorage, and clinical delivery platform in China. This initiative is in collaboration with Shenzhen Inno Immune and Wuhan Kaien Hospital, aiming to enhance accessibility to regenerative medicine across the region. The platform is designed to ensure centralized quality control while providing decentralized access for patients. This expansion reflects EUDA's commitment to transforming healthcare in Asia with a focus on longevity and preventive care.
Read more →EUDA Health to Launch EUDA Helix 2.0 in January 2026 SINGAPORE
EUDA Health Holdings Limited has announced the upcoming launch of its enhanced supplement, EUDA Helix 2.0, set for January 2026. The new version features an upgraded formulation with increased potency due to a rise in deer placenta powder and a shift from L-glutathione to Vitamin E for better antioxidant stability. Additionally, EUDA Helix 2.0 employs advanced preservation and delivery technologies aimed at enhancing nutrient absorption and extending shelf life. The product has also secured New Zealand Halal certification, enabling broader distribution across international markets, particularly in Muslim regions.
Read more →Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen
EUDA Health Holdings Limited has announced the launch of a comprehensive stem cell therapy platform and the establishment of its first clinic in Shenzhen, China. This initiative aims to accelerate its longevity and regenerative medicine strategy, supported by strategic partnerships and advanced technology. The upgraded facility will enhance production capabilities for stem cell treatments, and the new clinic will introduce integrated longevity healthcare services. This move positions EUDA to leverage the growing market for longevity-focused healthcare in Asia.
Read more →Integrates QB Utility Token to Create a Digital Health and Rewards Platform Across Its Healthcare Ecosystem
EUDA Health Holdings Limited has announced the integration of the QB utility token into its digital health and rewards platform, enhancing customer engagement across its healthcare services. The token, issued by Hong Kong-based QB Limited, allows customers to earn and redeem rewards for services such as Bioenergy Capsule treatments and supplements. The integration aims to create a unified digital ecosystem, leveraging advanced blockchain infrastructure for secure, traceable transactions. EUDA is positioning itself to lead in the non-invasive healthcare market across Asia with this innovative approach.
Read more →Plans to Integrate QB Utility Token into Its Healthcare Ecosystem
EUDA Health Holdings Limited announced its plan to integrate a utility cryptocurrency called QB into its healthcare ecosystem. This initiative aims to create a digital health and rewards platform for payments and access to EUDA's services, enhancing customer engagement through a connection between healthcare and decentralized finance. The QB coins, scheduled for launch in January 2026, will also support EUDA's financial strategies as part of a broader mission to address evolving healthcare needs in Asia. CEO Alfred Lim highlighted the potential of this integration to transform health engagement into tangible economic value.
Read more →EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement
EUDA Health Holdings Limited announced a securities purchase agreement with Streeterville Capital for a convertible warrant worth $100,000. This warrant allows for the acquisition of up to 2 million shares at $6 each and is part of the company's strategy to boost capital for growth initiatives. CEO Alfred Lim emphasized the financing's role in expanding EUDA's footprint in the non-invasive healthcare market across Asia, targeting a demographic with changing healthcare needs.
Read more →Subsidiary CK Health Plus Expands into India in Strategic Partnership with SafeRock India
EUDA Health Holdings Limited's subsidiary, CK Health Plus, has announced its expansion into India through a strategic partnership with SafeRock India. This collaboration aims to leverage SafeRock India's infrastructure and network to introduce cutting-edge Bioenergy Capsule Therapies and EUDA Helix supplements across major cities like Mumbai and Bangalore. The partnership is designed to address the growing demand for preventive healthcare solutions in the Indian market, aligning with the shift towards healthier lifestyles among consumers.
Read more →EUDA Subsidiary CK Health Plus Secures Malaysia Direct Selling License, Strengthening Its Longevity Business Across Asia
EUDA Health Holdings Limited's subsidiary, CK Health Plus, has obtained a Direct Selling License from the Malaysian government, enabling it to operate direct selling and multi-level marketing activities. This license will facilitate the nationwide rollout of wellness product distribution and Bioenergy Capsule Centers in Malaysia. CK Health Plus intends to create a sustainable business model that integrates healthcare, education, and entrepreneurship, with a focus on preventive health solutions. The company's strategic expansion reflects its commitment to addressing the healthcare needs of a rapidly aging population in the region.
Read more →EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30
EUDA Health Holdings Limited released its unaudited condensed consolidated balance sheets as of June 30. The report primarily outlines various financial components under US GAAP standards, reflecting on the company's assets, liabilities, and equity. Details include categories such as retained earnings and common stock, among others, although specific financial figures are not disclosed in the text provided.
Read more →